Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
G1 Therapeutics Inc. (GTHX) is a clinical-stage biopharmaceutical company pioneering novel therapies through its kinase-targeted drug discovery platform. This page provides centralized access to official news and developments related to their oncology pipeline, including treatments for extensive-stage small cell lung cancer and triple-negative breast cancer.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated feed includes verified information about small-molecule therapies, chemoprotective agents, and collaborative research initiatives aimed at improving cancer treatment outcomes.
Key categories cover FDA communications, trial phase results, intellectual property developments, and financial reporting. All content is sourced directly from company releases and reputable financial news outlets to ensure accuracy.
Bookmark this page to stay informed about G1 Therapeutics' advancements in reducing chemotherapy side effects and developing precision oncology treatments. Check regularly for updates on their clinical-stage assets and partnership-driven growth strategy.
G1 Therapeutics (GTHX) announced significant data presentations at the ASCO annual meeting, scheduled for June 4-8, 2021. Key highlights include results on the oral selective estrogen receptor degrader, rintodestrant, in combination with palbociclib for treating ER+/HER2- advanced breast cancer. Additionally, findings regarding COSELA™ (trilaciclib) and its impact on T-cell activation for small cell lung cancer patients will also be shared. Posters will be accessible on the company’s website starting June 4, 2021.
G1 Therapeutics (GTHX) presented two posters at ISPOR, highlighting the economic impact of COSELA (trilaciclib) for treating myelosuppression in extensive-stage small cell lung cancer (ES-SCLC). A cost-benefit model indicates potential savings of $15,006 per patient due to reduced adverse events when using COSELA prior to chemotherapy. Additionally, an analysis of SEER-Medicare data demonstrates the significant healthcare burden of myelosuppression, with high rates of anemia (74.3%) and neutropenia (45.2%) among chemotherapy patients.
G1 Therapeutics has initiated the PRESERVE 4 clinical trial, a Phase 2 study evaluating the survival and myeloprotection benefits of COSELA™ (trilaciclib) in 146 patients with non-small cell lung cancer (NSCLC) previously treated with checkpoint inhibitors. The trial will assess the anti-tumor efficacy of COSELA when administered before docetaxel chemotherapy. Results are expected in the first half of 2023. The primary focus is on overall survival compared to placebo, with secondary endpoints targeting progression-free survival and myeloprotection.
G1 Therapeutics (GTHX) announced the grant of 40,000 inducement stock options to five new employees as part of its 2021 Inducement Equity Incentive Plan. This move, in line with Nasdaq Rule 5635(c)(4), aims to incentivize new hires. The stock options have an exercise price of $20.86, the May 3, 2021 closing price, and will vest over four years. G1 Therapeutics is dedicated to developing therapies for cancer treatment, including their first product, COSELA™.
G1 Therapeutics announced a corporate and financial update for Q1 2021, highlighting total revenue of $14.2 million, including $0.6 million from the initial sales of COSELA, its FDA-approved therapy for chemotherapy-induced myelosuppression. COSELA has been included in two National Comprehensive Cancer Network® guidelines, aiding reimbursement decisions. A pivotal Phase 3 trial for metastatic triple-negative breast cancer is ongoing. Cash reserves stand at $279 million, sufficient to fund operations into 2023, with a net loss of $26.4 million.
G1 Therapeutics, Inc. (GTHX) announced a webcast and conference call scheduled for May 5, 2021, at 4:30 p.m. ET, to provide a corporate and financial update for Q1 2021. The call can be accessed via domestic and international dialing. G1 Therapeutics, based in Research Triangle Park, focuses on developing next-generation therapies for cancer, including its first product, COSELA™ (trilaciclib), and has a clinical pipeline targeting various solid tumors such as colorectal, breast, lung, and bladder cancers.
G1 Therapeutics (GTHX) has initiated the PRESERVE 2 study, a pivotal Phase 3 trial evaluating COSELA (trilaciclib) in patients with locally advanced unresectable or metastatic triple-negative breast cancer (mTNBC). This randomized, double-blind study will enroll 250 patients undergoing first- or second-line gemcitabine and carboplatin chemotherapy. The primary goal is to assess COSELA's impact on overall survival compared to placebo, with results expected in the second half of 2023, highlighting a potential breakthrough in mTNBC treatment.
G1 Therapeutics announced the publication of positive results from three clinical trials of COSELA™ (trilaciclib) for treating extensive-stage small cell lung cancer (ES-SCLC) in Clinical Lung Cancer. The pivotal studies demonstrated that COSELA significantly reduced chemotherapy-induced myelosuppression compared to placebo, leading to decreased hematologic adverse events and supportive care needs. This enhancement in patient outcomes did not compromise the efficacy of chemotherapy. COSELA was FDA-approved in February 2021 to mitigate myelosuppression when used before specific chemotherapy regimens.
G1 Therapeutics, a commercial-stage oncology company, will have CEO Jack Bailey participate in the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 12:45 PM EDT. This event will be held virtually, and the webcast can be accessed via the company's Events & Presentations page. G1 is focused on developing innovative cancer therapies, including COSELA™ (trilaciclib), and has a strong pipeline targeting various solid tumors such as colorectal, breast, lung, and bladder cancers.
G1 Therapeutics (GTHX) announced the grant of inducement stock options for 46,300 shares to eight new employees under its 2021 Inducement Equity Incentive Plan. This aligns with Nasdaq Listing Rule 5635(c)(4) and is aimed at attracting individuals who were not previously employed by the company. The stock options have an exercise price of $23.72 per share, reflecting the closing price on the grant date of April 1, 2021. Each option has a ten-year term and vests over four years, contingent on continued service.
